TrialThe oncologist2020

An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas.

Ming-Huang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.